Literature DB >> 8805744

Pharmacologic characterization in vitro and in vivo of iodine 123-labeled derivatives of the beta-adrenoceptor antagonist CGP12177, designed for the imaging of cardiac beta-receptors.

E A Dubois1, G A Somsen, J C van den Bos, A G Janssen, G J Boer, H D Batink, E A van Royen, M Pfaffendorf, P A van Zwieten.   

Abstract

BACKGROUND: Potential new radioligands for the noninvasive imaging of cardiac beta-adrenoceptors with single-photon emission computed tomography were investigated. METHODS AND
RESULTS: Two iodinated derivatives of CGP12177 para (S-CYBL2B) and ortho (CYBL2A) substituted CGP12177 and an iodinated form of nadolol (CYBL1) were synthesized. Their affinity was tested in vitro (left ventricular homogenates). The biodistribution of [123I]S-CYBL2B was evaluated in rabbits. Specific binding was assessed by pretreatment of the animals with 0.1 mumol propranolol. The inhibition constant values (in nanomolars, means +/- SEM; n = 3 to 5) were determined at 1.17 +/- 0.42, 28800 +/- 9260, 11.1 +/- 2.1, 53.0 +/- 19.9, and 1790 +/- 700 for CGP12177, CYBL2A, S-CYBL2B, nadolol, and CYBL1. Myocardial uptake of [123I]S-CYBL2B was not inhibited by pretreatment of the animals with propranolol, but uptake by lung tissue could be blocked by propranolol (0.63% +/- 0.09% vs 0.33% +/- 0.02% % injected dose/g x kg; p < 0.05). In isolated right atria, preincubation with S-CYBL2B induced a parallel rightward shift of the concentration-response curve with isoprenaline.
CONCLUSIONS: S-CYBL2B shows high affinity for cardiac beta-adrenoceptors, but binding proved nonspecific in vivo, whereas binding in lung tissue was specific. These results suggest that S-CYBL2B is probably not a suitable radioligand for receptor imaging.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8805744     DOI: 10.1016/s1071-3581(96)90038-0

Source DB:  PubMed          Journal:  J Nucl Cardiol        ISSN: 1071-3581            Impact factor:   5.952


  34 in total

Review 1.  Mechanisms involved in adrenergic receptor desensitization.

Authors:  S Collins; M Bouvier; M J Lohse; J L Benovic; M G Caron; R J Lefkowitz
Journal:  Biochem Soc Trans       Date:  1990-08       Impact factor: 5.407

2.  Plasma membrane-specific deficiency in cardiac beta-adrenergic receptor in streptozocin-diabetic rats.

Authors:  A Kashiwagi; Y Nishio; Y Saeki; Y Kida; M Kodama; Y Shigeta
Journal:  Am J Physiol       Date:  1989-08

3.  Beta 1- and beta 2-adrenergic-receptor subpopulations in nonfailing and failing human ventricular myocardium: coupling of both receptor subtypes to muscle contraction and selective beta 1-receptor down-regulation in heart failure.

Authors:  M R Bristow; R Ginsburg; V Umans; M Fowler; W Minobe; R Rasmussen; P Zera; R Menlove; P Shah; S Jamieson
Journal:  Circ Res       Date:  1986-09       Impact factor: 17.367

Review 4.  Beta-adrenergic function in heart muscle disease and heart failure.

Authors:  M R Bristow; N E Kantrowitz; R Ginsburg; M B Fowler
Journal:  J Mol Cell Cardiol       Date:  1985-07       Impact factor: 5.000

Review 5.  Beta receptor antagonists in the treatment of heart failure.

Authors:  H Persson; L Erhardt
Journal:  Cardiovasc Drugs Ther       Date:  1991-06       Impact factor: 3.727

Review 6.  Novel approaches to congestive heart failure: use of beta-adrenergic blockade.

Authors:  E J Eichhorn; P Sobotka
Journal:  Coron Artery Dis       Date:  1994-02       Impact factor: 1.439

Review 7.  Beta blockers in heart failure.

Authors:  F Waagstein
Journal:  Cardiology       Date:  1993       Impact factor: 1.869

8.  Cardiac autonomic receptors: effect of long-term experimental diabetes.

Authors:  J Latifpour; J H McNeill
Journal:  J Pharmacol Exp Ther       Date:  1984-07       Impact factor: 4.030

Review 9.  Changes in myocardial and vascular receptors in heart failure.

Authors:  M R Bristow
Journal:  J Am Coll Cardiol       Date:  1993-10       Impact factor: 24.094

Review 10.  Controlled trials with beta blockers in heart failure: metoprolol as the prototype.

Authors:  M B Fowler
Journal:  Am J Cardiol       Date:  1993-03-25       Impact factor: 2.778

View more
  1 in total

1.  Detection of the secondary, low-affinity β1 -adrenoceptor site in living cells using the fluorescent CGP 12177 derivative BODIPY-TMR-CGP.

Authors:  K Gherbi; S J Briddon; S J Hill
Journal:  Br J Pharmacol       Date:  2014-12       Impact factor: 8.739

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.